Century Therapeutics, Inc. (IPSC)
NASDAQ:IPSC
Want to see IPSC full AI Analyst Report?
IPSC Stock Chart & Stats
$2.60
<$0.01(0.47%)
At close: 4:00 PM EST
$2.60
<$0.01(0.47%)
Day’s Range― - ―
52-Week Range$0.44 - $3.04
Previous CloseN/A
Volume712.78K
Average Volume (3M)825.87K
Market Cap
$398.58M
Enterprise Value$204.99M
Total Cash (Recent Filing)$134.80M
Total Debt (Recent Filing)$43.94M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding180,354,810
10 Day Avg. Volume1,130,327
30 Day Avg. Volume825,873
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-68.24
Enterprise Value/Ebitda-2.11
Forecast
1Y Price Target
$5.90Price Target Upside126.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Modest Leverage / Strong Balance Sheet FootingModest leverage and a relatively healthy balance sheet provide structural financial flexibility for a clinical‑stage biotech. Lower debt reduces interest burden and bankruptcy risk, making it easier to fund multi-year development programs and absorb clinical setbacks without forcing immediate dilutive financing.
Strategic Collaborations And Extended RunwayMaterial collaboration revenue and an oversubscribed $135M private placement materially extend cash runway into 2029. This structural support reduces near‑term financing pressure, enabling the company to hit development milestones (INDs, first‑in‑human studies) without immediate dependence on capital markets.
Platform And Manufacturing Progress (CNTY‑813)Demonstrated preclinical durability and an established Phase 1 manufacturing process are durable fundamental positives. They validate the iPSC platform and reduce clinical and scale‑up execution risk, supporting regulatory filings and giving Century a differentiated program in diabetes alongside oncology assets for long‑term opportunity diversification.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow is a structural constraint: ongoing cash burn necessitates external funding rounds or partnerships to sustain R&D and trials. Over the medium term this pressures strategic choices, can delay programs if funding tightens, and increases dependency on capital markets or partners.
Volatile, Lumpy Revenue And Negative Gross ProfitLumpy collaboration income and a TTM revenue drop to zero with negative gross profit signal poor near‑term commercial sustainability. This volatility weakens predictability for funding and operations, complicates long‑range planning and makes the company reliant on milestone payments rather than recurring product sales.
Dilution Risk From ATM / Equity ProgramsAn active ATM with substantial available capacity provides financing flexibility but represents structural dilution risk. Reliance on equity issuance to fund development can dilute existing shareholders and may influence capital allocation, possibly prioritizing short‑term funding over long‑term value creation.
Century Therapeutics News
IPSC FAQ
What was Century Therapeutics, Inc.’s price range in the past 12 months?
Century Therapeutics, Inc. lowest stock price was $0.43 and its highest was $3.04 in the past 12 months.
What is Century Therapeutics, Inc.’s market cap?
Century Therapeutics, Inc.’s market cap is $398.58M.
When is Century Therapeutics, Inc.’s upcoming earnings report date?
Century Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 57 days.
How were Century Therapeutics, Inc.’s earnings last quarter?
Century Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.048.
Is Century Therapeutics, Inc. overvalued?
According to Wall Street analysts Century Therapeutics, Inc.’s price is currently Undervalued.
Does Century Therapeutics, Inc. pay dividends?
Century Therapeutics, Inc. does not currently pay dividends.
What is Century Therapeutics, Inc.’s EPS estimate?
Century Therapeutics, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Century Therapeutics, Inc. have?
Century Therapeutics, Inc. has 180,354,810 shares outstanding.
What happened to Century Therapeutics, Inc.’s price movement after its last earnings report?
Century Therapeutics, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -0.437%.
Which hedge fund is a major shareholder of Century Therapeutics, Inc.?
Currently, no hedge funds are holding shares in IPSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Century Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.90 (126.92% Upside)
$5.90 (126.92% Upside)
Blogger Sentiment
Bullish
IPSC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 33.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 4.1%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
244.15%
12-Months-Change
Fundamentals
Return on Equity
-53.23%
Trailing 12-Months
Asset Growth
3.47%
Trailing 12-Months
Company Description
Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
IPSC Stock 12 Month Forecast
Average Price Target
$5.90
▲(126.92% Upside)
Technical Analysis
Tempest Therapeutics
―
Actinium Pharmaceuticals
―
Bioxcel Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
3.46% Insiders
3.48% Mutual Funds
58.78% Other Institutional Investors
31.02% Public Companies and
Individual Investors